Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (September 2005)
23 slides from Resonance Health's shareholder meeting presentation, Sep 22, 2005
Slide 1: General Meeting Presentation September 2005
Resonance. General Meeting Presentation September 2005 ©Resonance Health Limited 2005 4
Slide 2: Our Mission
Our Mission We develop and market systems to assist in the diagnosis and management of patients suffering from “Iron Overload” conditions. Our products and services deliver significant added value for our customers and tangible benefits to patients. ©Resonance Health Limited 2005 2
Slide 3: Company overview
Company overview. Resonance. Resonance Health Limited is an ASX listed healthcare company Resonance is the developer of FerriScan® FerriScan is a unique, non-invasive test for measuring iron overload in the liver FDA, CE and TGA marketing clearance Low cost, high margin business model — MRI scans in
Slide 4: Capital structure
Capital structure. Ordinary Shares on Issue: Market Capitalisation (at 5 September closing): Performance Shares (Class F+G): Options: Resonance. 185,494,023 $25.0 million 16,000,000 Listed RHTOA options — ($0.15 ex to Sep 05) 3,000,000 $0.4m Listed RHTOA options — ($0.15 ex to 15 Jan 07) 47,461,309
Slide 5: An experienced and trusted team
An experienced and Resonance. trusted team. Executive Management Dr James Williams Managing Director Mr Glenn Smith Director Marketing & Sales Associate Professor Tim St. Pierre Chief Scientific Officer Dr Janet Preuss Regulatory Affairs Manager Board The Hon. Dr Michael Wooldridge Chairman Mr Tony
Slide 6: Iron overload diseases
Iron overload diseases. * Iron overload conditions are amongst the most os tron overload in target organs common human diseases, with approximately : 500 million people either symptomatic or : carriers of the defective gene(s) bosocyes The heatmexcessive + lron toxicity is a major cause of organ dam
Slide 7: An identified need globally
An identified need globally. Resonance: *In the USA it is estimated that 67% of HHC patients are misdiagnosed and see an average of three doctors before obtaining a successful diagnosis * Current gold standard: Liver Needle Biopsy * Invasive, Painful & Dangerous * Expensive * Inaccurate * Current to
Slide 8: FerriScan: An innovative, high-tech service
FerriScan: Resonance. An innovative, high-tech service. *A safe, non-invasive and accurate test to measure and monitor liver iron concentration * Uses Magnetic Resonance Imaging (MRI) * Scan is interpreted by proprietary software * Validated against current “gold standard” (Liver Biopsy) * Regulator
Slide 9: A better test than current 'Gold Standard'
FerriScan: Resonance A better test than current ‘Gold Standard’. Nature of test Invasive Non-invasive Patient comfort Painful Painless Risk of procedure Potentially fatal Safe Accuracy Current Standard Equivalent => better Average length of hospital stay 1-2 days 0.5 hours Average cost to hospital/H
Slide 10: In diagnostic services, speed, accuracy and cost matter
In diagnostic services, Resonance’ speed, accuracy and cost matter. * Clinicians want more effective and lower medical (and legal) risk diagnostic techniques « Patients want and expect higher and higher levels of service/care « MRI chains want increase ROI on equipment and greater market share * OEM
Slide 11: Achievements to date
Achievements to date. Resonance. * Oct 04: Peer reviewed clinical publications; * Nov 04: Australian Government grant to develop fibrosis test; * Dec 04 / Jan 05: Key regulatory clearances (TGA, FDA and CE Mark); * Feb 05: DCA Group (Australia’s largest diagnostic imaging group) confirmed as partner
Slide 12: A low cost, high margin business model
A low cost, high margin Resonance: business model. Radiology _ N | transmitted practices with ; ; | Raw MRI liver images Ri scanners © ; : are sent via the internet Enabled to utilise | to Resonance Health. FeriScan — ’ technology. oe Resonance Health's Central image Analysis Centre Proprietary soft
Slide 13: FerriScan: Significant addressable market
FerriScan: Significant addressable Resonance market. Population Haemochromatotics' 264,000 : 1.2M Clinically significant iron overload? 200,000 “ 760,000 1. Based on published incidence rate of 1:227 2. 1/3 of those peopie having persistently elevated blood iron markers (including haemochromatotics
Slide 14: Commercial progress: Sales commenced & leading clinical sites active
Commercial progress: Sales Resonance. commenced & leading clinical sites active. Australia: 9 sites _ ___U.K Launch Q1 FY2006 *DCA ‘ + Public hospitals USA: 7 sites + Pharma and Thalassemia Clinical Research Network UK: 3 sites USA sites Q1 FY2006 + MedTel * Public Hospitals EU/ROW: 5 sites + Pharma
Slide 15: CY2006: Rollout targets and model
CY2006: Rollout targets and model. Resonance. Current June 2006 ©Resonance Health Limited 2005 15
Slide 16: Substantial potential for revenue growth
Substantial potential for revenue growth. Revenue $6.4M Scans 21,600 (% Market) (0.8%) Revenue Scans (% Market) Revenue $17.2M Scans 57,600 (% Market) (2.1%) Revenue $21.6M 500 Scans 72,000 (% Market) (2.6%) Assumes: 12 scans/month/MRI @ $300 / scan Market: Refers to % US, EU, UK and Aus addressable
Slide 17: CY2006 targets
CY2006 targets: Resonance: Solid foundations in place. On track to have 130+ FerriScan-enabled MRI sites by June 2006 Forecast to be cash flow positive during CY2006 + Significant radiology partners in place, others to follow * Commercial customers already in place (Novartis, TCRN) — sites being act
Slide 18: Outlook / Strategy
Outlook / Strategy. Resonance: * Expand channel partner activation and leverage their marketing capability * Engage opinion leaders as ambassadors for FerriScan’s benefits and insert into clinical guidelines * Inform patient (groups) about FerriScan + Foster expanded Pharma relationships + Engage or
Slide 19: Our activities
Our activities. Resonance. * One-on-one sales calls * Trial stage and site training + Awareness campaign to early adopters « Australian launch « UK pre-launch + Disease Association engagement + Re-branding — awareness building * Medical Advisory Board * Further promotion to Specialists + Engagement
Slide 20: Pipeline: new applications and new products
Pipeline: new applications Resonance! and new products. Diversification and product improvements Expanded clinical applications: Co-develop, publish and market expanded clinical algorithms Pharmaceutical industry: Use in clinical studies where iron levels may affect drug performance or is an appropr
Slide 21: Summary
Summary. Resonance: * FerriScan is now commercially available * FerriScan will become the new gold standard for measurement of Liver Iron Concentration * Resonance Health is generating revenue from product sales and is positioned for growth * Commercial partners in place —- DCA, Novartis, US Radiolo
Slide 22: Contacts
Contacts. Resonance. Dr James Williams Managing Director Email: jamesw(@ferriscan.com Ph: +61 8 9286 5300 Glenn Smith Marketing Director Email: cenns@ferriscan.com Ph: +61 8 9286 5300 ©Resonance Health Limited 2005 22
Slide 23: Forward looking statements and risks
Forward looking statements Resonance. and risks. This presentation contains forward-looking statements that are based on management’s current expectations. These statements may differ materially from actual future events or results due to the range of risks and uncertainties associated with the heal
Resonance Health — Shareholder Meeting (September 2005) on 6ix